Research Roundup: Engineered Nanoparticles and New Potential Standards of Care
Positive results from a phase 3 trial of Astellas Pharmaceuticals’ zolbetuximab and modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) “may represent a... Read More
Research Roundup: Mushroom Consumption and Lowered Risk
In a clinical trial, patients with gastric cancer who received low-dose olanzapine during chemotherapy experienced improved appetite and weight gain over those... Read More
The Gut Microbiome Offers Clues to Immunotherapy Efficacy in Advanced Gastric Cancer
Japanese researchers found a link between the gut microbiome and a positive response to the immunotherapy drug Opdivo in patients with gastric... Read More
UArizona Health Sciences Researchers Find Biomarker that Can Appear Before Stomach Cancer Develops
Researchers at the University of Arizona discovered a biomarker that appears in people before stomach cancer develops and that can be detected... Read More
Fluctuating expression of miR-584 in primary and high-grade gastric cancer
A recent study found that H. Pylori infection raises levels of a particular miRNA, which could be used as a biomarker for... Read More
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
A study showed that Cyramza with paclitaxel improved survival in gastric cancer over paclitaxel alone.
Treatment Efficacy in Metastatic Esophageal, Gastric, or Gastroesophageal Cancer According to Expression of ERCC1
The biomarker ERCC1 is of interest for predicting sensitivity to platinum-based chemo, but a recent study in the Journal of Clinical Oncology... Read More
Guardant’s blood test tracks microsatellite instability status on par with tissue biopsy in new study
In a trial involving 949 patients with 40 tumor types, including gastric cancer, a blood test from Guardant Health was as good... Read More
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Researchers evaluated the addition of the AKT inhibitor ipatasertib to mFOLFOX6 for patients with gastric cancer.
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends
A review of evolving trends in third line treatment of advanced gastric cancer shows sequential treatment approaches benefit a growing minority of... Read More